Abstract:Background:Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL) both have consistent expression of CD30, a cytokine receptor that is expressed by activated T and B cells but is largely absent from normal tissue.Methods:A literature search was conducted via PubMed, Google Scholar, and UpToDate to identify relevant peer-reviewed original research or review articles on HL, sALCL, and CD30 targeted therapies.Results:These lymphomas are both more common among males, young adults and the elderly. Although many patients with HL and sALCL can achieve long-term remission after standard first-line therapy, up to a third of these patients are refractory to or relapse after initial therapy. Among these relapsed/refractory patients, many experience disease progression and/or death despite subsequent treatment, and treatment-related adverse events and mortality are not uncommon. To address the need for safer and more effective therapies for these relapsed/refractory patients, researchers have developed therapies that specifically target CD30-expressing cells. Brentuximab vedotin, an antibody-drug conjugate that selectively delivers a toxic microtubule-disrupting agent to malignant cells with CD30 expression, is the first such therapy to be approved in the US and Europe. In clinical trials, brentuximab vedotin has demonstrated efficacy and safety in patients with HL after failure of autologous stem cell transplantation (ASCT), or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and in patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.Conclusion:HL and sALCL are both CD30+ lymphomas, and therapies like brentuximab vedotin that target cells expressing CD30 hold promise for the treatment of these diseases.

CD30 expression in a case of intravascular large B‐cell lymphoma, cutaneous variant

CD30 expression defines a novel subgroup of diffuse large B cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL …

Cd30 Expression Defines A Novel Subgroup Of Diffuse Large B-Cell Lymphoma With Favorable Prognosis And Distinct Gene Expression Signature: A Report From The International Dlbcl Rituximab-Chop Consortium Program Study

Effective Management of a Rare Case of Primary Renal Intravascular Large B-cell Lymphoma with Modified R-CHOP Regimen: A Case Report

Clinical and Biological Significance of De Novo CD5+ Diffuse Large B-cell Lymphoma in Western Countries.

Intravascular Large B-cell Lymphoma with Cutaneous Manifestations: a Clinicopathologic, Immunophenotypic and Molecular Study of Three Cases

Relation of CD30 expression to survival and morphology in large cell B cell lymphomas.

Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities

Current progress and future perspectives of research on intravascular large B‐cell lymphoma

Detection of CD30 Expression in Lymphomas: Status and Challenges

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Intravascular Large B-cell lymphoma: A case series and review of literatures

Update of the Diagnosis and Treatment of Intravascular Large B-cell Lymphoma

CD30 expression and prognostic significance in R-EPOCH–treated patients with diffuse large B-cell lymphoma

Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma

CD30 Expression and Its Correlation with MYC Rearrangement in De Novo Diffuse Large B-cell Lymphoma.

The Epidemiology And Targeted Therapies For Relapsed And Refractory Cd30+Lymphomas

Prevalence and Clinicopathologic Features of CD30-positive De Novo Diffuse Large B-cell Lymphoma in Chinese Patients: a Retrospective Study of 232 Cases.

Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma

[Intravascular Large B-cell Lymphoma: a Clinical Analysis of 17 Cases].

Intravascular large B-cell lymphoma:a clinicopathological analysis of 2 cases